The Potential Protective Effects of Statins in Chronic Rhinosinusitis: A Case-Control Study.
HMG-CoA
Statin
adult
airway
cholesterol
chronic rhinosinusitis
clinic
enzyme
inflammation
inhaled
lower
medication
oral
otolaryngology
pharmacology
prevention
protective
pulmonary
sinus
synthesis
therapy
treatment
upper
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
28
09
2020
received:
01
09
2020
accepted:
05
10
2020
pubmed:
4
11
2020
medline:
11
5
2021
entrez:
3
11
2020
Statut:
ppublish
Résumé
To determine the potential protective effect of prior statin use on the subsequent diagnosis of chronic rhinosinusitis (CRS). Retrospective, case-control. Electronic medical records for all patients seen in the otolaryngology clinic in 2019 and receiving a diagnosis of CRS were reviewed for the presence or absence of active prior statin use within 365 days of the visit. Similarly, prior statin use in a control group of patients without any diagnosis of CRS was also determined. Statin exposure in CRS patients was compared to statin exposure in control patients with 1:2 matching on age and sex with chi-square and odds ratios were computed. In 2019, 3655 patients (mean age, 52.9 years, 56.4% female) were identified with a diagnosis of chronic rhinosinusitis versus 41,636 patients without any diagnosis of CRS. All chronic rhinosinusitis patients were successfully matched to 7310 controls. 6.3% of CRS patients (229 patients) had prior statin use, versus 8.5% (624 patients) of control patients. The average mean duration of statin use prior to visit was not significantly different between CRS and control patients (mean days, 202.3 days versus 205.6 days, respectively; P = .697). The presence of a statin medication in use was associated with a significant protective effect against a subsequent diagnosis of CRS with and odds ratio for CRS diagnosis of 0.716 (95% confidence interval, 0.612-0.838) in those patients taking a statin medication (P < .001). The use of a statin medication was associated with a significant reduction in subsequent diagnosis of chronic rhinosinusitis. 3 Laryngoscope, 131:E1431-E1433, 2021.
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E1431-E1433Informations de copyright
© 2020 American Laryngological, Rhinological and Otological Society Inc, "The Triological Society" and American Laryngological Association (ALA).
Références
Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: a systematic review. Laryngoscope 2015;125:1547-1556.
Centers for Disease Control and Prevention. National Center for Health Statistics. Chronic Sinusitis. Centers for Disease Control and Prevention. National Center for Health Statistics. Chronic Sinusitis. Available at: http://www.cdc.gov/nchs/fastats/sinuses.htm. Updated July 06, 2016. Accessed October 08, 2020.
Bhattacharyya N. Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States. Ann Otol Rhinol Laryngol 2011;120:423-427.
Bhattacharyya N, Gilani S. Prevalence of potential adult chronic Rhinosinusitis symptoms in the United States. Otolaryngol Head Neck Surg 2018;159:522-525.
Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015;152:S1-S39.
Scangas GA, Wu AW, Ting JY, et al. Cost utility analysis of Dupilumab versus endoscopic sinus surgery for chronic Rhinosinusitis with nasal polyps. Laryngoscope 2020. Online ahead of print.
Bhattacharyya N. Clinical outcomes after revision endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 2004;130:975-978.
Wang W, Le W, Ahuja R, Cho DY, Hwang PH, Upadhyay D. Inhibition of inflammatory mediators: role of statins in airway inflammation. Otolaryngol Head Neck Surg 2011;144:982-987.
Dehnavi S, Sohrabi N, Sadeghi M, et al. Statins and autoimmunity: state-of-the-art. Pharmacol Ther 2020;214:107614.
Wilson JH, Payne SC, Fermin CR, Churnin I, Qazi J, Mattos JL. Statin use protective for chronic rhinosinusitis in a nationally representative sample of the United States. Laryngoscope 2020;130:848-851.
Bradbury P, Traini D, Ammit AJ, Young PM, Ong HX. Repurposing of statins via inhalation to treat lung inflammatory conditions. Adv Drug Deliv Rev 2018;133:93-106.
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-1862.
Zeki AA, Elbadawi-Sidhu M. Innovations in asthma therapy: is there a role for inhaled statins? Expert Rev Respir Med 2018;12:461-473.
Alberts AW, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme a reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A 1980;77:3957-3961.
Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope 2003;113:1199-1205.